mTOR inhibition improves immune function in the elderly
Novartis (United States) · Novartis (Italy) · +3 more institutions
Abstract
Inhibition of the mammalian target of rapamycin (mTOR) pathway extends life span in all species studied to date, and in mice delays the onset of age-related diseases and comorbidities. However, it is unknown if mTOR inhibition affects aging or its consequences in humans. To begin to assess the effects of mTOR inhibition on human aging-related conditions, we evaluated whether the mTOR inhibitor RAD001 ameliorated immunosenescence (the decline in immune function during aging) in elderly volunteers, as assessed by their response to influenza vaccination. RAD001 enhanced the response to the influenza vaccine by about 20% at doses that were relatively well tolerated. RAD001 also reduced the percentage of CD4 and…
Citation impact
- FWCI
- 20.60
- Percentile
- 100%
- References
- 23
Authors
12Topics & keywords
- Immunosenescence
- PI3K/AKT/mTOR pathway
- Immune system
- Immunology
- Life span
- Medicine
- Mechanistic target of rapamycin
- Sirolimus